---
title: "Dizal Pharmaceutical Co., Ltd. (688192.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688192.SH.md"
symbol: "688192.SH"
name: "Dizal Pharmaceutical Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T15:22:02.016Z"
locales:
  - [en](https://longbridge.com/en/quote/688192.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688192.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688192.SH.md)
---

# Dizal Pharmaceutical Co., Ltd. (688192.SH)

## Company Overview

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.dizalpharma.com](https://www.dizalpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 25 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 104.01% |  |
| Net Profit YoY | 18.07% |  |
| P/B Ratio | 19.12 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 23737695393.35 |  |
| Revenue | 895606218.24 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -106.48% | E |
| Profit Margin | -74.62% | E |
| Gross Margin | 95.92% | A |
| Revenue YoY | 104.01% | A |
| Net Profit YoY | 18.07% | B |
| Total Assets YoY | 66.94% | A |
| Net Assets YoY | 5148.47% | A |
| Cash Flow Margin | 98.51% | C |
| OCF YoY | 104.01% | A |
| Turnover | 0.37 | C |
| Gearing Ratio | 59.01% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Dizal Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "104.01%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "18.07%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "19.12",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "23737695393.35",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "895606218.24",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-106.48%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-74.62%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "95.92%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "104.01%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.07%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "66.94%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "5148.47%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "98.51%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "104.01%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "59.01%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -36.26 | 64/81 | - | - | - |
| PB | 19.51 | 77/81 | 20.49 | 19.00 | 16.43 |
| PS (TTM) | 27.06 | 77/81 | 66.65 | 48.92 | 38.78 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 52.00 |
| Highest Target | 99.75 |
| Lowest Target | 83.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688192.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688192.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688192.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**